ArticleFrontiers in cellular and infection microbiology2026
Unveiling the anti-inflammatory power of star anise-cinnamon compound essential oil against MDR
Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: This study aimed to investigate the antiinfi ammatory effects and potential molecular mechanisms of star anise-cinnamon compound essential oil (SCEO) against multidrug-resistant Salmonella Thompson (MDR S. Thompson) infection in mice. Methods: An intestinal infection model was established in mice by oral gavage of MDR S. Thompson (1×109 CFU/mL) for two consecutive days. Experimental animals were randomly assigned to a blank group, a model group, a levofioxacin group (positive control), and SCEO low-, medium-, and high-dose groups (100, 200, and 400mg/kg, respectively). Results and Discussion: SCEO intervention significantly alleviated clinical symptoms in infected mice, restored pathological damage in the liver and ileum, and normalized the liver index. Gas chromatography-mass spectrom- etry (GC-MS) analysis identified trans-cinnamaldehyde and trans-anethole as the primary active components of SCEO. Network pharmacology and molecular docking analyses revealed strong binding affinities between these components and Toll-like receptor 4 (TLR4), RELA, and mitogen-activated protein kinase 14 (MAPK14) (Vina score < -5.0 kcal/mol). Further in vivo and in vitro experiments demonstrated that SCEO significantly downregulated the mRNA expression of key cytokines, including Tlr4, interleukin-6 (Il6), tumor necrosis factor (Tnf), and interleukin-17A (Il17a), and suppressed the overactivation of the TLR4/nuclear factor kappa-B (NFĸB)/MAPK signaling pathway. SCEO effectively alleviated Salmonella-induced infiammatory damage, a protective process potentially me- diated through the modulation of the TLR4/NFĸB/MAPK signaling axis. These findings provide a theoretical basis for the development of SCEO as a natural, plant-derived anti-infective agent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.